A North American coatings technology company with differentiated IP and established customer relationships was facing strategic uncertainty following a stalled transaction process and divergent shareholder objectives. The business was perceived as a niche solutions provider for the consumer electronics rather than a differentiated scalable platform.
- Repositioned the company as a functional coatings platform with cross-industry applications
- Clarified the technology stack and its role within customer manufacturing processes
- Separated core operating value from non-core transaction noise and legacy process dynamics
- Stabilized the narrative around commercial traction, IP relevance, and scalability
- Advised on transaction structuring and stakeholder alignment in a complex, multi-party environment
- Re-established a coherent strategic narrative for the asset
- Preserved optionality across transaction pathways
- Enabled stakeholders to engage from a position of clarity rather than process fatigue
- Maintained buyer interest despite prior process disruption
Strategic repositioning • Transaction structuring • Stakeholder alignment • Process advisory • Negotiation support
A European synthetic biology CRO was viewed as an R&D cost center, with limited commercial structure and a complex revenue mix.
- Reframed the company as a core innovation engine in synthetic biology
- Positioned capabilities within the design–build–test–scale value chain
- Clarified revenue quality and addressed equity-linked components transparently
- Built a platform integration thesis for strategic buyers
- Prepared and executed a disciplined sell-side process
- Re-established a coherent strategic narrative for the asset
- Shifted perception from service provider to strategic upstream asset
- Created a clear integration story for buyers
- Enabled underwriting based on strategic fit rather than standalone earnings
Strategic repositioning • Revenue analysis • Buyer mapping • Process management • Diligence support